**TITLE:**

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

**AUTHORS AND AFFILIATIONS:**

Shikha Tarang1, Umesh Pyakurel1, Songila M. S. R. Doi1, Michael D. Weston1, Sonia M. Rocha-Sanchez1

1Department of Oral Biology, Creighton University School of Dentistry, Omaha, NE, USA

**E-mail Addresses of the Co-authors:**

Shikha Tarang (shikhatarang@creighton.edu)

Umesh Pyakurel (umeshpyakurel@creighton.edu)

Songila M. S. R. Doi (songila35@gmail.com)

Michael D. Weston (MichaelWeston@creighton.edu)

**Corresponding Author:**

Sonia M. Rocha-Sanchez (ssanchez@creighton.edu)

**KEYWORDS:**

Dominant-negative, retinoblastoma, preprocathepsin (CB), reversible, inducible, transgenic

**SUMMARY:**

Here we present a protocol to develop a dominant-negative inducible system, in which any protein can be conditionally inactivated by reversibly overexpressing a dominant-negative mutant version of it.

**ABSTRACT:**

Dominant-negative (DN) protein inhibition is a powerful method to manipulate protein function and offers several advantages over other genome-based approaches. For example, although chimeric and *Cre-LoxP* targeting strategies have been widely used, the intrinsic limitations of these strategies (*i.e.*, leaky promoter activity, mosaic *Cre* expression, *etc.*) have significantly restricted their application. Moreover, a complete deletion of many endogenous genes is embryonically lethal, making it impossible to study gene function in postnatal life. To address these challenges, we have made significant changes to an early genetic engineering protocol and combined a short (transgenic) version of the Rb1 gene with a lysosomal protease procathepsin B (CB), to generate a DN mouse model of Rb1 (CBRb). Due to the presence of a lysosomal protease, the entire CB-RB1 fusion protein and its interacting complex are routed for proteasome-mediated degradation. Moreover, the presence of a tetracycline inducer (rtTA) element in the transgenic construct enables an inducible and reversible regulation of the RB1 protein. The presence of a ubiquitous ROSA-CAG promoter in the CBRb mouse model makes it a useful tool to carry out transient and reversible Rb1 gene ablation and provide researchers a resource for understanding its activity in virtually any cell type where RB1 is expressed.

**INTRODUCTION:**

Most approaches aiming at the gene and protein ablations rely on permanent processes, which generally lead to the complete elimination or truncation of the gene, RNA sequences, or protein of interest (POI). The overall goal of this method is to engineer a recombinant protein to abolish the function of endogenous, wild-type protein. We have revisited and revamped an alternative strategy1,2, which allows for the temporary ablation of a POI through DN inhibition. This method works for both multimeric and monomeric peptides but is best suited for proteins that function in a multimeric assembly.

The method consists of fusing the lysosomal protease CB to a subunit of a multimeric POI (CB fusion complex). The resultant CB fusion complex can interact with and proteolytically digest the endogenous protein or divert the entire CB-POI complex to the lysosome to be degraded3. Moreover, a combination of the CB fusion complex with the inducible nature of the tetracycline-controlled transcriptional activation (TetO) system allows for an inducible and controlled expression of the transgene in a reversible fashion2. Although useful in many circumstances, the complete deletion of genes or proteins *in vivo* can result in lethality4-6. Likewise, tissue-specific, conditional deletion of some genes or proteins using the Cre/Lox system may not be straightforward, as it will, ultimately, lead to the permanent loss of critical genomic elements7. Therefore, depending on the gene or POI, neither of these approaches will be effective in providing a useful model for subsequent studies, particularly genes’ or proteins’ functional studies in late postnatal and adult mice.

To circumvent the problems associated with such approaches and provide proof-of-principle on the effectiveness of the proposed method, we have chosen to test the method presented here by generating a conditional DN version of the Retinoblastoma 1 (RB1) protein. Several options have been proposed8-10 to abolish the function of endogenous RB1; however, all of them faced some of the same limitations discussed above: permanent germline deletion of RB1 is embryonically lethal, and, consistent with its tumor suppressor role, permanent RB1 conditional deletion leads to a variety of tumors11. Even though a DN version of RB1 does not seem to occur naturally, a better alternative to the currently available strategies should allow for a temporally controlled inactivation of the endogenous RB1 and provide an alternative mechanism to eventually restore its function. The basis for such a construct was described over two decades ago1. However, due to technological limitations, it lacked a mechanism to control transgene activation, response, and tissue specificity. This study is the first to combine the elegance of the doxycycline (Dox)-dependent transcriptional system with an engineered transgenic construct of lysosomal protease CB and *Rb1* proteins. The resulting CBRb mouse model allows for a temporarily regulated Dox-mediated RB1 regulation2. The advantage of using such a proteome-based approach to study gene function is that it can be adopted for any gene of interest, with minimal information on its activity.

The proposed DN transgene strategy offers many advantages over traditional approaches. First, DN protein inhibition leads to only a *partial* ablation in protein activity, thus preserving a residual endogenous expression. Such an outcome is highly desirable in situations where a complete elimination of protein activity leads to embryonic lethality, greatly limiting any investigation to study gene function in a live mouse. Second, the presence of the TetO system enables transgene activation only in the presence of an antibiotic, which allows for an efficient and *reversible* control of the transgene activity. Thus, by ceasing the antibiotic administration, the transgenic system can be deactivated, and a normal RB1 expression is back in place. Third, the specificity of the transgene expression can vary depending on the promoter of choice. While we have chosen the ubiquitous ROSA-CAG promoter for proof-of-principle, placing the transgene under a tissue-specific promoter is likely to restrict unwanted transgene expression and facilitate studies on the therapeutic application of this transgene methodology.

**PROTOCOL:**

Generation of the transgenic CBRb mouse and all animal care and experiments associated with the study were approved by the Creighton University Institutional Animal Care and Use Committee (IACUC) and performed by their guidelines.

**1. Transgenic CB-Myc6-Rb1 Construct**

Note: The cloning of CBRb into a pTet\_Splice vector was done in a multi-step process (**Figures 1A** and **1B**).

1.1. Perform the first stage cloning into the pCS2+CB-Myc6 vector.

1.1.1.To create the CBRb transgene construct, amplify a 1583-bp-long *Rb1* cDNA fragment (528 amino acids corresponding to the amino acid region 369 - 896) of the RB1 protein using the following primer set: for EcoRI+**RB 1243**F, use GGGGAATTCA**TTAAATTCAGCAAGTGATCAACCTTC**, and for XbaI+EcoRV+**RB 2826**R, use CCCTCTAGATATCTA**TTTGGACTCTCCTGGGAGATGTTTACTTCC**.

1.1.2. Clone the fragment generated (1546 bp) between the *EcoR1* and *XbaI* restriction sites of the pCS2+CB-Myc6 vector as previously described1,12.

Note: The 1012-bp-long CB-Myc6 construct (337 amino acids) fused to the *Rb1* fragment resulted in a protein of approximately 865 amino acids (about 108 kDa), which is slightly smaller than the endogenous RB1 protein (~110 kDa) (**Figure 1A**), with a CB-Myc6 tag at the N-terminus and *Rb1* at the C-terminus.

1.2. Perform the second stage subcloning into the pTet-Splice vector.

1.2.1. To amplify the CB-RB-Myc6 fusion fragment and to gain the Tet-promoter, amplify the cassette, consisting of the *CB-myc6-Rb1* using primers containing the *EcoRV* (XbaI+EcoRV+RB 2826R) and *SalI* sites: for SalI+**CB**F, use CCAGTCGACAGG**ATGTGGTGGTCCTTGATCCTTC**.

1.2.2. Subclone the fragment generated (2567 bp) into the pTet-Splice vector, between the *SalI* and *EcoRV* restriction sites, in such a way that the entire *TetO-DN-CB-myc6-Rb1* transgene, including the SV40 intron and the PolyA signal, can be isolated through a single digestion with *NotI* (**Figure 1B**).

Note: The NotI fragment was used to generate the transgenic funders.

2. *In Vitro* Testing of the *TetO-DN-CB-myc6-Rb1* Transgene

2.1. Dox-regulation: NIH3T3 cell line

Note: Unless otherwise stated, all volumes have been adjusted for a 6-well plate.

2.1.1. Grow NIH3T3 cells following the vendor’s specifications, using the recommended cell culture media containing 10% fetal bovine serum at 37 °C with 10% CO2.

2.1.2. Cotransfect the cells with pTet-Splice and pCMV-Tet3G vectors (from step 1) for 24 h. Follow the steps mentioned below for cotransfection.

2.1.2.1. Mix 2 - 4 µL of the lipid-based transfection reagent/well and 1 mL of incomplete (without serum) Dulbecco’s Modified Eagle Medium‎ (DMEM) for 5 min at room temperature. For a 12- or 24-well plate, use 250 or 500 µL of culture media, respectively, and adjust the transfection reagent volume accordingly.

2.1.2.2. Add 2 - 3 µg of plasmid DNA/well to the transfection reagent-DMEM and incubate for 20 min at room temperature.

2.1.2.3. Add the mix containing DNA and the transfection reagent in DMEM to each well. After 3 - 4 h of incubation, add 1 mL of complete media (so that the final volume is 2 mL/well). Keep aliquots of Dox stock (1 mg/mL) and add 2 µL in each of the wells (+ Dox). Incubate the cells at 37 °C with 5% CO2.

Note: Control samples should consist of cotransfected cells not treated with Dox (- Dox), as well as NIH3T3 cells transfected only with the transactivator pCMV-Tet3G vector and treated with Dox for a 24-h period. For pCMV-Tet3G, concentrations of 0.1 - 1 µg/mL Dox should be sufficient to induce the transgene expression.

2.2. Test the reversibility of the construct using the HEK293 cell line.

2.2.1. To test the reversibility of the *TetO-DN-CB-myc6-Rb1* transgene, culture HEK293 cells in Eagle’s Minimum Essential Medium (EMEM) following the vendor’s specifications and cotransfect with both pTet-Spliceand pCMV-Tet3G vectors for 24 h, as described above (step 2.1.2).

2.2.2. For the transgene inactivation, remove the Dox-containing media after 24 h, wash the cells 2x - 3x with phosphate buffered saline (PBS) and incubate them in Dox-free media for an additional 24 h.

Note: Upon Dox-removal, the transgene inactivation and regular protein expression should be resumed within that 24-h period.

2.3. To assess the functionality of the *TetO-DN-CB-myc6-Rb1* construct in promoting unscheduled cell proliferation, perform the functional analyses using an HEI-OC1 cell line, as described below.

2.3.1. Culture HEI-OC1 cells in 10% DMEM under permissive conditions (33 °C with 10% CO2). For cell proliferation studies, count the cells using a cell counter, and plate 10,000 HEI-OC1 cells on a 96-well plate in a 200-µL volume. Incubate the cells overnight.

2.3.2. On the following day, perform a transient cotransfection of pTet-Splice and pCMV-Tet3G vectors using a lipid-based transfection reagent (see steps 2.1.2). In a separate well, perform pmR-ZsGreen1 transfection at 2-µg using the lipid-based transfection reagent (steps 2.1.2) to calculate the transfection rate. Use non-transfected cells as controls.

2.3.3. Detect the presence of green fluorescence under a fluorescence microscope (excitation = 485 nm, emission = 530 nm) for the transfected cells 24 h after transfection. Record the presence or absence of green fluorescence and calculate the rate of transfection as the total number of GFP-positive cells (transfected cells) over the cells labeled with DAPI (total cells).

Note: We estimated a transfection rate of ~70%.

2.3.4. To induce transgene expression, add 1 µg/mL Dox to a subset of transfected cells while using the other subset as control (-Dox). Use untreated HEI-OC1 cells as additional controls.

2.3.5. To assess cell proliferation, use a cell proliferation kit according to the manufacturer’s protocol.

2.3.5.1. In brief, 48 h after transfection, remove the cell culture medium and add 100 μL of 1x dye-binding solution to each well of the microplate. Incubate for 1 h at 37 °C.

2.3.5.2. Thereafter, measure the fluorescence intensity of each sample using a fluorescence microplate reader (excitation = 485 nm, emission = 530 nm).

2.3.6. To further assess cell proliferation using immunocytochemistry, plate the HEI-OC1 cells on a cover glass in a 12-well plate and incubate overnight at 37 °C.

2.3.6.1. On the following day, cotransfect with the pTet-Splice and pCMV-Tet3G and perform the Dox treatment (+ Dox). Use untransfected cells as controls. Process HEI-OC1 cells for Ki-67 labeling.

2.3.6.2. Fix the cells with 4% paraformaldehyde (PFA) in PBS, pH 7.4, for 10 min at room temperature. Wash the cells 3x with ice-cold PBS and incubate the cells in 0.25% non-ionic detergent in PBS for 10 min.

2.3.6.3. Wash the cells again, 3x in PBS for 5 min, and block using 10% serum in a humidified chamber for 1 h at room temperature.

2.3.6.4. Incubate the cells in 500 µL of Ki-67 primary antibody (1:200 dilution) for 3 h at room temperature or overnight at 4 °C.

2.3.6.5. Wash the cells 3x for 5 min with PBS. After that, incubate the cells with the secondary antibody for 1 h at room temperature in the dark.

2.3.6.6. Remove the secondary antibody solution and wash the cells 3x with PBS for 5 min each in the dark.

2.3.6.7. For phalloidin labeling, incubate the HEI-OC1 cells in 1:200 phalloidin for 30 min. To label the nuclei of cells, incubate the cells with 5 µg/mL DAPI for 10 min at room temperature.

Note: Ensure that the phalloidin dye conjugate is different than the secondary antibody conjugate.

3. Generation of CBRb+/ROSA-CAG-rtTA+ (CBRb) Transgenic Mice and *In Vivo* Testing of the DN-CBRb Approach

3.1. Upon confirmation of the effective Dox regulation of the *TetO-DN-CB-myc6-Rb1* transgene, purify the NotI fragment and microinject them into mouse zygotes, which are later transferred into pseudo-pregnant females.

Note: These procedures were carried out at the University of Nebraska Medical Center (UNMC) Mouse Genome Engineering Core Facility.

3.2. After delivery, genotype the pups using a primer set specific to the *CB-Rb1* fusion region: for CBRb F, use 5’ CTGTGGCATTGAATCAGAAATTGTGGCTGG 3′, and for CBRB R, use 5′ GTACTTCTGCTATATGTGGCCATTACAACC 3′.

Note: The PCR product size observed on agarose gel is 401 bp (60-bp CB region + 341-bp *Rb1* region (Table 1). Ten independent founder lines were identified, based on the presence of the *TetO-DN-CB-myc6-Rb1* transgene. In five of these lines, progeny inherited the transgene, which confirmed the germline transmission of the transgene. One of the transgenic lines was ultimately used to establish and maintain the line and generate experimental *TetO-DN-CB-myc6-Rb1* animals for further studies.

3.3. Breed adult *TetO-DN-CB-myc6-Rb1* mice to the *ROSA-CAG-rtTA* tetracycline inducer line (Stock #006965) (alternatively, breed to a tTA inducer line) to generate experimental DN-CBRb mice. Genotype the offspring of this cross using the following primer set: for rtTA-WT R, use GGAGCGGGAGAAATGGATATG; for rtTA Mutant R, use GCGAGGAGTTTGTCCTCAACC; and for rtTA Common, use AAAGTCGCTCTGAGTTGTTAT. The PCR product sizes are 340 bp (mutant), 340 bp and 650 bp (heterozygote), and 650 bp (wild-type).

3.4. Generate a dose-response curve of the RB1 protein following the Dox treatment to determine the time and length of the Dox treatment necessary to elicit a transgene expression.

Note: In this experiment, western blot and qRT-PCR were used to assess tissue-specific transgene activation and RB1 expression.

3.5. Perform fluorescence *in situ* hybridization (FISH) to confirm the genomic insertion of the transgene.

Note: This was carried out at the Centre for Applied Genomics of the Hospital for Sick Children (Toronto, Canada). ELISA or western blotting (using protein-specific antibody) can be used to assess transgene activation, tissue-specificity, and changes in the levels of the endogenous POI. For the *DN-CB-myc6-Rb1* construct, we used an anti-RB1 antibody.

**REPRESENTATIVE RESULTS:**

Generally, designing a DN mutation requires a considerable amount of information on the structure and function of the POI. In contrast, the DN strategy presented here is particularly useful when the structural and functional information for the POI is limited. If the POI is a multimeric protein, a fusion of one subunit to a lysosomal protease can dominantly inhibit the assembled multimer and, potentially, other ligands through a combination of proteolysis of the endogenous subunits and subcellular diversion of the multimer to the lysosome. To confirm successful cloning and test the effectiveness of Dox-regulated transgene activation, purified pTet-Splice plasmid containing the *TetO-DN-CB-myc6-Rb1* construct was transfected into mouse NIH3T3 cells that stably expressed the rtTA protein, but not Rb113. In the absence of Dox, cells expressing rtTA displayed no RB1 expression, whereas a robust RB1 expression was observed in the presence of Dox (**Figure 2A**). Next, to test the reversibility of the system, we cotransfected HEK293 cells (which endogenously express *Rb1*14) with purified pTet-Splice/*TetO-DN-CB-myc6-Rb1* and the pCMV-Tet3G vectors. As expected, the expression of the endogenous RB1 protein was significantly inhibited on transgene activation by the addition of Dox in the cell culture media (**Figure 2B**). To test the reversibility of the system, following a 24-h period, in a subset of HEK293 cells, we replaced the Dox-containing cell culture media with fresh Dox-free media and incubated the cells for an additional 24 h. Supporting the Dox-regulated reversibility, RB1 expression was restored upon Dox removal from the culture media (**Figure 2B**).Transfected HEK293 cells that were not treated with Dox or Dox-treated HEK293 cells transfected with the pCMV-Tet3G vector only (**Figure 2B**) showed basal levels of endogenous RB1 expression. Because NIH3T3 cells do not express RB1 protein naturally, the positive RB1 reactivity is due to the accumulation of the transgenic RB1 protein. Given our interest in the potential proliferative effect of the *TetO-DN-CB-myc6-Rb1* construct in the auditory system, we measured the total DNA content in pTet-Splice/*TetO-DN-CB-myc6-Rb1*- and pCMV-Tet3G-transfected HEI-OC1 cells (inner ear organ of a Corti-derived cell line) in the presence and absence of Dox. Consistent with the working hypothesis presented here, a significant increase in the DNA content (corresponding to an increase in cell number) was observed in Dox-treated but not untreated (control) transfected HEI-OC1 cells (**Figures 3A** - **3C**).

Following the *in vitro* confirmation of the transgene activity and function, a transgenic mouse model was generated. FISH, using a *TetO-DN-CB-myc6-Rb1* digoxigenin (DIG)-horse radish peroxidase (HRP)/tyramine-biotin/avidin-Cy5-labeled probe, and G-banding of male mice splenocytes and ear fibroblasts were performed to confirm the transgene insertion in the transgenic mice genome. Among the five germline transmitting founders, line 14 showed a consistent transgene insertion within segment 10C3~D2 (**Figures 4A** - **4C**). Mice from this line were used to establish the breeding colonies and generate experimental animals for further studies. To determine the optimum time for the Dox induction and *TetO-DN-CB-myc6-Rb1* transgene activation, we divided the transgenic mice into three different groups, wherein Dox was administered in drinking water for variable lengths of time: **Group 1** (3 days of treatment), **Group 2** (7 days of treatment), and **Group 3** (10 days of treatment). Upon completion of the treatment, changes in the RB1 protein expression were assessed by western blotting (**Figures 5A - 5D**). Because the DN and native RB1 proteins have similar molecular weights, they cannot be resolved from each other on a western blot. However, consistent with an initial increase in RB1 protein (due to the accumulation of DN-RB1 and endogenous proteins), there was an initial increase in total RB1 protein expression in the transgenic mouse cochleae compared to the control group (**Figure 5A**). Moreover, consistent with the inhibitory and proteolytic activity of the *TetO-DN-CB-myc6-Rb1* transgene product, a quantifiable reduction in RB1 expression was observed in groups 2 and 3 compared to group 1 and control groups (**Figures 5A** - **5D**). Of note, treatment longer than 10 days did not result in any further change in RB1 protein expression. Thus, 10 days of Dox treatment was considered optimal and used for further studies.

Because the rtTA and, consequently, *TetO-DN-CB-myc6-Rb1* transgene activation are under the ubiquitous *ROSA-CAG* promoter, RB1 could be potentially inhibited in any tissue or cell where RB1is endogenously expressed (*e.g.*, lungs, heart, retina). To test this premise and evaluate the transgene’s tissue specificity, cochleae, lungs, heart, and eye biopsies were dissected from *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA*, and control mice (not carrying the *ROSA-CAG-rtTA* transgene) were assessed for RB1 expression (**Figures 6A** - **6C**). Regardless of the tissue analyzed, a significant reduction in RB1 protein was observed in *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA* but not in the control group (**Figure 6A**). In sharp contrast, qRT-PCR analyses in the eye, heart, and cochleae of Dox-treated *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA* and age-matched control mice showed a significant upregulation of the DN-CBRb transcript in the tissues of the former but not the latter mice (**Figure 6C**). Altogether, these results confirm the efficiency of the construct. An increase in transcript expression reflects the effective Dox-regulated transgene induction. Likewise, a reduction in protein expression is consistent with the routing and proteolytic degradation of the endogenous RB1.

**Figure Legends:**

**Figure 1:** **Multi-step cloning of the CBRb and generation of the inducible *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA*.** (**A**) This panel shows the cloning of the *Rb1* fragment into the *pCS2-CB-Myc6* vector. A 1583-bp *Rb1* gene product was PCR amplified using the *EcoRI+RB1243* forward and *Xba+EcoRV+RB2826* reverse primers. The resulting *Rb1* fragment was cloned between the *EcoRI* and *Xbal* restriction sites of the pCS2 vector containing the *CB-Myc6* construct to generate the *pCS2+CB-myc6+Rb1* vector. (**B**) The *CB-myc6+Rb1* fragment was cloned into the *pTetSplice* vector between the *SalI* and *EcoRV* restriction sites.

**Figure 2:** **Effectiveness of the Dox-regulated transgene activation.** (**A**) NIH3T3 cells do not usually express RB113. Confirming the efficient activation of the *TetO-DN-CB-myc6-Rb1* construct, a western blot analysis with the anti-RB1 antibody revealed a robust RB1 expression in the presence of Dox (lanes 1 and 3), but not in its absence (lanes 2 and 4). (**B**) HEK293 cells, which endogenously express *Rb1*14, were cotransfected with *TetO-DN-CB-myc6-Rb1* and the pCMV-Tet3G transactivator vector. In the absence of Dox (lane 1), a positive RB1 expression was observed. The addition of Dox to the system caused the *TetO-DN-CB-myc6-Rb1* activation and RB1 downregulation (lane 2). The RB1 expression was resumed 24 h after Dox was removed from the media (lane 3). C = control, untransfected HEK293 cells not treated with Dox. This is an adaptation from a figure originally published in the journal *Frontiers in Cellular Neuroscience*2. Its reproduction agrees with *Frontiers*’ policy on authors’ copyright retention.

**Figure 3: Dox-mediated DN-CBRb transgene activation increases cell proliferation.** (**A**) HEI-OC1 cells cotransfected with purified *TetO-DN-CB-myc6-Rb1*, and the pCMV-Tet3G vectors were cultured in the absence (−) or presence (+) of Dox. Cell proliferation was determined 48 h after the transfection using a proliferation assay. The percentage change in proliferation was calculated using a change in fluorescence values with untransfected cells as a control. A modest but significant increase in cell number was observed in the transfected cells, following Dox treatment. In contrast, no significant changes were observed between transfected HEI-OC1 cells not treated with (−) Dox and the untransfected control. (**B**) HEI-OC1 cells untransfected or (**C**) cotransfected with purified TetO-DN-CB-myc6-Rb1 and the pCMV-Tet3G vectors cultured in the presence (+) of Dox were labeled with Ki-67 (red), Phalloidin (green), and DAPI (blue). \* *P* < 0.05. The scale bar = 10 µm. This is an adaptation from a figure originally published in the journal *Frontiers in Cellular Neuroscience*2. Its reproduction agrees with *Frontiers*’ policy on authors’ copyright retention.

**Figure 4: Fluorescent *in situ* hybridization (FISH) confirmation of the genomic insertion of the *TetO-DN-CB-myc6-Rb1* transgene.** A pCS2-CBRb (digoxigenin probe/anti-DIG-HRP/tyramide-biotin/avidin-Cy5, in red) test probe was hybridized to splenocytes and ear fibroblast cell metaphase to see if the probe signal could be detected or not with a one-copy target insert size of 2.5 kb. The pCS2-CBRb test probe hybridized to one chromosome 10 with bright, doublet probe signals that showed the insertion of the *TetO-DN-CB-myc6-Rb1* transgene within the segment 10C3-D2. The RP23-267G24 (Spectrum Green) control probe hybridized to chromosome 10 at band 10A1 as expected and confirmed that the CBRb DNA of interest inserted into chromosome 10. (**A**) This panel shows the G-band metaphase. (**B**) This panel shows the tyramide signal amplification (TSA) FISH image from the same metaphase as shown in panel **A**. (**C**) This panel shows composite images of chromosome 10 showing (1) G-banding, (2) TSA FISH, and (3) TSA FISH with inverted DAPI banding. Red = pCS2-CBRb probe; blue = DAPI banding; green = RP23-267G24 control probe. The scale bar = 10 µm.

**Figure 5: DN-CBRb transgene activation in the inner ear of postnatal (P) 36 *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA+* (CBRb+) and *ROSA-CAG-rtTA*+ (CBRb−) mice after 3 (group 1), 7 (group 2), and 10 (group 3) days of Dox treatment**. (**A** – **C**) Anti-RB1, which reacts with both hyperphosphorylated and hypophosphorylated forms of RB1, as well as anti-c-myc antibodies were used for detection. Densitometric analysis was done using ImageJ software. The corresponding values obtained were normalized to the negative control CBRb− (-) and then to β-actin. The relative RB1 expression levels are shown underneath each blot. (**D**) **The** graphic representation of normalized RB1 expression levels plotted against the different treatments highlights a consistently lower RB1 detection in CBRb+ (+) samples. Each lane on the western blot gel and each column on the graphic correspond to a different individual. \* *P* < 0.05. This figure was originally published in the journal *Frontiers in Cellular Neuroscience*2. Its reproduction agrees with *Frontiers*’ policy on authors’ copyright retention.

**Figure 6: Spatial analyses of the *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA* transgene activation in P18 *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA+* (+) and DN-CBRb+/*ROSA-CAG-rtTA*− negative control (-) mice heart, eye, lungs, and cochlea**. (**A**)Confirming the efficiency of Dox-mediated transgene activation, the expression of the endogenous RB1 was downregulated in the CBRb+/*ROSA-CAG-rtTA*+ tissues but not in the negative control mice tissues. Densitometric analysis was performed as described in **Figure 5**. The relative RB1 expression levels are shown underneath each blot. (**B**)This panel shows a graphic representation of normalized RB1 expression levels plotted against the different tissues. An interindividual variation on endogenous RB1 levels may explain differences in individual responses to transgene activation and RB1 downregulation. (**C**)RT-PCR analyses in eye, heart, and cochleae revealed a significant upregulation of the *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA* transcript in Dox-treated *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA+* tissues, but not in the DN-CBRb+/*ROSA-CAG-rtTA*− negative control group. CBRb+/rtTA+ = *TetO-DN-CB-myc6-Rb1/ROSA-CAG-rtTA*+; CBRb−/rtTA+ = *ROSA-CAG-rtTA+*; \* *P* < 0.05. This figure was originally published in the journal *Frontiers in Cellular Neuroscience*2. Its reproduction agrees with *Frontiers*’ policy on authors’ copyright retention.

**Table 1: PCR condition used for checking the *CB-Rb1* fusion region.**

**DISCUSSION:**

To circumvent the limitations associated with traditional transgenic strategies, we sought to generate a mouse model in which an endogenous POI can be conditionally inactivated by overexpressing a DN mutant form of it in a spatiotemporal manner. To abolish the function of endogenous POIs, several options have been proposed15-17. We have modified an earlier genetic strategy1 by combining the Dox-dependent transcriptional system to a straightforward strategy employing a fusion of the lysosomal protease CB to generate a mutant peptide whose expression affects the expression of the endogenous POI2. Most importantly, this technique requires no prior knowledge of the pathway associated with the POI. The current strategy to DN protein inhibition demonstrates that the lysosomal localization signal on the CBRb fusion gene diverts the entire RB-interacting complex toward lysosome2,3.Once inside lysosome, proteolytic processing of these proteins is initiated, leading to their degradation3. The intrinsic property of the CB-fused protein, associated with the reversible inducibility of the TetO system, makes this a useful alternative to traditional transgenic strategies (*e.g.*, complete gene knockout, conditional deletion), particularly when the complete deletion of the gene of interest is not desirable.

We initially focused the research on the RB1 protein. DN mutations are most easily described in proteins that function as a dimer or multimers. To date, there is no evidence of a direct physical interaction between RB1 molecules. Nonetheless, the inherent nature of its activity allows for the presence of multiple RB1 molecules in the same complex at a given time. For example, the binding of hypophosphorylated RB1 to the E2F1-DP heterodimer provides an additional binding site, which is normally occupied by histone deacetylase (HDAC)18-20. On the other hand, HDAC1 physically interacts with RB1 and this complex, in turn, binds to the E2F1-DP-RB1 heterotrimer, thus providing additional transcription repression18. As per this approach, if at least one of the RB1 molecules in the group is a DN mutant, it will prevent the complex from repressing transcription, while it reduces the levels of endogenous RB1, thus eliciting an RB1-null phenotype. Here, endogenous RB1 inhibition was observed 10 days after the administration of Dox in drinking water.The optimal dose for Dox induction may, however, need to be empirically determined for each system. Moreover, since most of the *Rb1* gene sequence was used on the construct makeup, it is possible that even in the absence of endogenous RB1, the mutant RB1 can interact with and elicit the DN inhibition of any of the RB1’s binding partners. This premise can be tested by assessing the expression level of known RB1-binding molecules.

Much-needed, finely regulated temporal and reversible proteininactivation will provide the basis for the development of a wide variety of studies in an even wider number of research fields searching to shed light on the complex biochemical mechanisms underlying the various aspects of gene and proteinactivity. Depending on the POI, understanding its molecular complexity is likely to improve researchers’ ability to design successful therapeutic strategies. Increased transgene specificity can be achieved by breeding the DN mouse to tissue-specific promoters driving either tTA or rtTA lines.

**ACKNOWLEDGMENTS:**

The pCS2+CB-Myc6 vector was a gift from Marshall Horwitz (University of Washington, Seattle, WA, USA). The HEI-OC1 cells were kindly provided by Fedrico Kalinec (David Geffen School of Medicine, UCLA, Los Angeles, CA, USA). Technical support was provided by the UNMC Mouse Genome Engineering Core (C.B. Gurumurthy, Don Harms, Rolen Quadros) and the Creighton University Integrated Biomedical Imaging Facility (Richard Hallworth, John Billheimer). The UNMC Mouse Genome Engineering was supported by an Institutional Development Award (IDea) from the NIH/NIGMS, grant number P20 GM103471. The Integrated Biomedical Imaging Facility was supported by the Creighton University School of Medicine and grants GM103427 and GM110768 from the NIH/NIGMS. The facility was constructed with support from grants from the National Center for Research Resources (RR016469) and the NIGMS (GM103427). The mouse lines generated in this study were maintained at Creighton University’s Animal Resource Facility, whose infrastructure was improved through a grant by NIH/NCRR G20RR024001. This work received past support through an NIH/NCRR 5P20RR018788-/NIH/NIGMS 8P20GM103471 COBRE grant (to Shelley D. Smith), NIH/ORIP R21OD019745-01A1 (S.M.R.-S.), and an emerging research grant from the Hearing Health Foundation (to S. Tarang). The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**DISCLOSURES:**

The authors have nothing to disclose.

**REFERENCES:**

1. Li, F.Q. *et al.* Preferential MyoD homodimer formation demonstrated by a general method of dominant negative mutation employing fusion with a lysosomal protease. *Journal of Cell Biology*. **135** (4), 1043-1057 (1996).

2. Tarang, S. *et al.*Generation of a retinoblastoma (rb)1-inducible dominant-negative (DN) mouse model. *Frontiers Cellular Neuroscience*. **9** (52) (2015).

3. Kominami, E. *et al.* The selective role of cathepsins B and D in the lysosomal degradation of endogenous and exogenous proteins. *FEBS Letters*. **287** (1-2), 189-192 (1991).

4. Cortellino, S. *et al.* Defective ciliogenesis, embryonic lethality and severe impairment of the sonic hedgehog pathway caused by inactivation of the mouse complex A intraflagellar transport gene Ift122/Wdr10, partially overlapping with the DNA repair gene Med1/Mbd4. *Developmental Biology.* **325** (1), 225-237 (2009).

5. Ferreira, C. *et al.* Early embryonic lethality of H ferritin gene deletion in mice. *Journal of Biological Chemistry.* **275** (5), 3021-3024 (2000).

6. Lee, E.Y. *et al.* Mice deficient for rb are nonviable and show defects in neurogenesis and haematopoiesis. *Nature*. **359** (6393), 288-294 (1992).

7. Turlo, K.A. *et al.* When cre-mediated recombination in mice does not result in protein loss. *Genetics*. **186** (3), 959-967 (2010).

8. Weber, T. *et al.* Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. *Proceedings of the National Academy of Sciences of the United States of America*. **105** (2),781-785 (2008).

9. Zhang, J. *et al.* The first knockout mouse model of retinoblastoma. *Cell Cycle*. **3** (7),952-959 (2004).

10. Zhao, H. *et al.* Deletions of retinoblastoma 1 (Rb1) and its repressing target S phase kinase-associated protein 2 (Skp2) are synthetic lethal in mouse embryogenesis. *Journal of Biological Chemistry.* **291** (19), 10201-10209 (2016).

11. Yamasaki, L. *et al.* Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. *Nature Genetics.* **18** (4), 360-364 (1998).

12. Li, F.Q. *et al.*Selection of a dominant negative retinoblastoma protein (RB) inhibiting satellite myoblast differentiation implies an indirect interaction between MyoD and RB*. Molecular and Cellular Biology.* **20** (14), 5129-5139 (2000).

13. Pitkanen, K. *et al.*Expression of the human retinoblastoma gene product in mouse fibroblasts: Effects on cell proliferation and susceptibility to transformation. *Experimental Cell Research*. **207** (1), 99-106 (1993).

14. Chano, T. *et al.* Neuromuscular abundance of RB1CC1 contributes to the non-proliferating enlarged cell phenotype through both RB1 maintenance and TSC1 degradation. *International Journal of Molecular Medicine*. **18** (3), 425-432 (2006).

15. Kole, R. *et al.* RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. *Nature Reviews Drug Discovery.* **11** (2), 125-140 (2012).

16. Yamamoto, A. *et al.* The ons and offs of inducible transgenic technology: A review. *Neurobiology of Disease*. **8** (6), 923-932 (2001).

17. Houdebine, L.M. *et al.* Transgenic animal models in biomedical research. *Methods in Molecular Biology*. **360**, 163-202 (2007).

18. Brehm, A. *et al.* Retinoblastoma protein recruits histone deacetylase to repress transcription. *Nature*. **391** (6667), 597-601 (1998).

19. Lu. Z. *et al.* E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. *Oncogene*. **25** (2), 230-239 (2006).

20. Magnaghi-Jaulin, L. *et al.* Retinoblastoma protein represses transcription by recruiting a histone deacetylase. *Nature*. **391** (6667), 601-605 (1998).